SUMO-C4H7NO2 probe, synthetic method and application

By designing the SUMO modification capture probe SUMO-C4H7N, the problem of detection of SUMO modification in cells is solved, and the localization and dynamic changes of SUMO modified proteins are monitored, which improves the accuracy of early diagnosis and prognosis evaluation of tumors such as breast cancer and other tumors , providing new ideas for cancer treatment.

CN118909621APending Publication Date: 2024-11-08DALIAN UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410979947.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The prior art is difficult to effectively detect and monitor the subcellular localization, modification degree and dynamic changes of SUMO modified proteins in cells, especially in tumor cells, which affect the early diagnosis and prognosis evaluation of malignant tumors.

Method used

A SUMO modified capture probe SUMO-C4H7N was designed to obtain human SUMO-1 protein through gene cloning, and a fluorescent probe was prepared in combination with chemical synthesis methods, which can specifically identify and quantitatively analyze SUMO modified proteins in cells to achieve their Monitoring of subcellular localization and dynamic modification changes.

Benefits of technology

Accurate localization and dynamic monitoring of intracellular SUMO modifications is achieved, improving the accuracy of tumor diagnosis and prognosis, and providing new target points to support cancer detection and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909621A_ABST
    Figure CN118909621A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and relates to an SUMOylation modified capture probe, a synthesis method and application. The molecular formula of the SUMOylation modified capture probe is SUMO-C4H7N, the SUMO is human SUMO-1, the nucleotide sequence of the SUMO is as shown in SEQ ID NO: 1, and the amino acid sequence of the SUMO is as shown in SEQ ID NO: 2. The polypeptide for coding the human SUMO-1 protein is obtained by adopting gene cloning, the SUMO-C4H7N is obtained by adopting a chemical synthesis method, and the SUMO-C4H7N is stable in structure and convenient for chemical synthesis and detection application. The SUMO-C4H7N fluorescent probe has high specificity and relatively high sensitivity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to a SUMO-modified capture probe, a synthesis method and an application thereof, and specifically refers to a SUMO-modified capture probe (SUMO-N-methylprop-2-yn-1-amine) (SUMO-C 4 H 7 N), its synthesis method and application in tumor detection. Background Art

[0002] Breast cancer is a malignant tumor that occurs in the mammary glands and ducts. It is the cancer with the highest incidence rate in women and one of the most common causes of morbidity and mortality in human diseases in the world today. It seriously threatens human life and health. Therefore, the prevention and treatment of breast cancer has become a global health issue and a disease that the World Health Organization focuses on preventing and treating. According to the data of the American Cancer Society (ACS), in the United States, the incidence rate of breast cancer is about 113.3 per 100,000 people. In my country, the incidence rate of breast cancer is increasing year by year. In many large cities, it has ranked first among female tumors, causing huge financial losses and mental pain to society and families.

[0003] At present, the pathogenesis of breast cancer is not fully understood, and there are no effective preventive measures. It is well known that the occurrence and development of most cancers, including breast cancer, is a long and chronic pathological change process. The current diagnostic methods for breast cancer can only diagnose cancer when the tumor has grown to a certain size, which is too late in many cases. The current treatment of breast cancer is still mainly drug therapy, radiotherapy and surgical resection, but there is no effective diagnosis and treatment method so far. Although surgery removes the tumor lesions, it also partially or completely removes the corresponding tissues and organs, losing their normal functions; while radiotherapy kills tumor cells with radiation, it also damages the body's normal tissue cells, which greatly limits tumor treatment; drug therapy has a weak efficacy and strong toxic side effects, which causes great physical and psychological trauma to patients. Like other cancers, the effective prevention and treatment of breast cancer also needs to clarify and explain the pathogenesis of breast cancer, so gene therapy is particularly important.

[0004] Small ubiquitin-related modifier (SUMO) modification is an important dynamic reversible protein post-translational modification, which has been discovered for more than 20 years. So far, more than 3,000 SUMO-modified proteins have been discovered and confirmed, and SUMO modification has important regulatory effects on the functions of target proteins, such as cell sublocalization, protein stability, signal transduction, enzyme activity, gene transcription regulation, cell cycle regulation, cell differentiation, etc. At present, four different SUMO protein subtypes have been identified in mammals, namely SUMO-1, SUMO-2, SUMO-3 and SUMO-4. With the participation of E1 activating enzyme, E2 conjugating enzyme and E3 ligase, the C-terminal diGly of SUMO molecules is covalently bound to the lysine side chain ε-NH2 on the target protein through an isopeptide bond, regulating the structure and function of the substrate protein. For example, SUMOylation of p53 occurs at the 386th lysine residue, and members of the PIAS (protein inhibitor of activatedSTATs) family can enhance the stability of p53. At the same time, studies have also confirmed that SUMOylation can enhance the transcriptional activity of p53, leading to cell apoptosis. Lysine residues at positions 254, 266, and 289 of the PTEN (phosphatidylinositol-3,4,5-trisphosphate-3-phosphatase) protein can be modified by SUMO-1 and SUMO-2, downregulating the PI3K / AKT pathway, thereby inhibiting cell proliferation and tumor growth. Multiple proteins that interact with p53 can be SUMOylated, and the role of core factors of signaling pathways such as NF-κB and PTEN in tumor development at least partially depends on the activity of SUMO proteins. Therefore, SUMOylation is one of the most promising targets for future cancer detection and treatment. By studying relevant SUMO fluorescent probes and understanding the dynamic changes in SUMOylation levels during tumor development, new ideas can be opened up for early diagnosis and treatment of tumors.

[0005] SUMOylation of proteins is a dynamic and reversible process, so deSUMOylation enzymes are considered to be drug therapeutic targets. DeSUMOylation enzymes (DSPs) are composed of a group of SUMO-specific protease family SENPs (Sentrin / SUMO-specific protease). SENPs can regulate the SUMOylation level and activity of target proteins, and their own expression or activity is also regulated by some regulatory factors. Through sequence alignment, it was found that SENPs all have an enzyme active region of about 200 amino acids, belonging to C48 cysteine ​​proteases, which can cut the isopeptide bond between SUMO and target proteins. Based on this characteristic of DSP, a molecular probe targeting cysteine ​​in the active center of DSP is designed, which can specifically recognize and covalently bind to cysteine ​​without cutting the isopeptide bond between SUMO and target proteins, so that deSUMOylation reaction will not occur.

[0006] Since SUMOylation is a dynamic process, it is very difficult to locate and dynamically detect SUMOylation in cells. Currently, there is an urgent need for a detection method to accurately locate and dynamically monitor SUMOylation. In particular, in some tumor cells, the degree of SUMOylation is closely related to the malignancy and prognosis of the tumor. Therefore, the cell localization, quantitative analysis and tracking of dynamic modification changes of SUMOylation will help in the diagnosis and prognosis of malignant tumors. Summary of the invention

[0007] In order to solve the problem in SUMOylation detection, the present invention provides a SUMOylation modification capture probe, which can quickly detect the subcellular localization, modification degree and dynamic modification change process of SUMOylation modified proteins in cells.

[0008] The technical solution of the present invention is:

[0009] A SUMOylation-modified capture probe, the molecular formula of which is SUMO-C 7 H 13 NO 2 , the structural formula is shown in the following formula (I):

[0010]

[0011] The SUMO is human SUMO-1, whose nucleotide sequence is shown in SEQ ID NO: 1, and whose amino acid sequence is shown in SEQ ID NO: 2.

[0012] The method for preparing the SUMO-modified capture probe comprises the following steps:

[0013] Step 1: Obtain the full-length cDNA sequence of human SUMO by gene cloning;

[0014] Step 2, the plasmid containing the full-length SUMO cDNA sequence obtained in step 1 is used to recombinantly express the SUMO protein polypeptide in Escherichia coli, and affinity purifies the SUMO protein polypeptide to obtain a pure SUMO protein polypeptide;

[0015] Step 3: The pure SUMO protein polypeptide obtained in step 2 is synthesized by a fully chemical method to obtain SUMO-C 4 H 7 N fluorescent probe.

[0016] The step 3 is as follows:

[0017] Step 3.1) Dissolve ethyl benzothiazole-2-carboxylate (3.5 g, 14.5 mmol) in DMSO (60 mL), then add hydrazine hydrate (mass fraction 70%, 1.1 mL, 35.2 mmol), reflux until the reaction is complete, and cool the system to room temperature.

[0018] Step 3.2) Add deionized water to the reaction product in step 3.1) and stir for half an hour to quench the reaction.

[0019] Step 3.3) Add the reaction product in step 3.2) to a thiophenol solution and adjust the final pH to 8.5; wherein the thiophenol solution is prepared by dissolving thiophenol in dimethyl sulfoxide, and the volume fraction of thiophenol is 2%.

[0020] Step 3.4) The mixture obtained in step 3.3) was dissolved in a solution of TFA and DCM in a volume ratio of 1:1, stirred at room temperature for 1 h, monitored by TLC, and the organic phase was concentrated in vacuo, and the residue was dried under vacuum overnight.

[0021] Step 3.5) The organic solvent in step 3.4) was dried by rotary evaporator, and then recrystallized with DMSO to obtain a light yellow solid powder, which was detected by mass spectrometry.

[0022] Step 3.6) Amine hydrolysis of Boc-protected SUMO1-Mesna: SUMO1-Mesna (8.8 mg, 3.33 mM) and Boc 2O (3.6 μL, 53 mM) was dissolved in 300 μL of DMSO. Then 1.6 μL of DIEA was added, stirred at room temperature for 1 h, and cold ether was added to precipitate Boc-protected SUMO1-Mesna. Subsequently, the ether precipitate was dissolved in 500 μL of DMSO. Then 5 mL of thiophenol solution was added, wherein the thiophenol solution was thiophenol dissolved in dimethyl sulfoxide, and the volume fraction of thiophenol was 2%. In addition, DIEA was added as an initiator and the reaction was carried out at 37 °C. The organic phase was precipitated with ice ether and dried after 2 h. Then a standard cleavage reagent (volume ratio of TFA:TIS:H 2 O=95:2.5:2.5) to remove the Boc group in the SUMO segment, and the crude product was obtained by precipitation with cold ether and centrifugation.

[0023] Step 3.7) 4 g of the light yellow powder (15.6 mmol) obtained in step 3.5) and 2 mg of the product obtained in step 3.6) were mixed, and 30 mL of toluene and 20 mL of K 2 CO 3 The reaction vessel was filled with N 2 After sealing, the mixture was placed in a shaker and reacted at 50°C and 150 rpm for 48 h to obtain SUMO1-NHNH 2 .

[0024] Step 3.8) The SUMO1-NHNH obtained in step 3.7) 2 (1 mM) was dissolved in a buffer containing 6.0 M GnHCl and 0.2 M Na 2 HPO 4 , pH 3.0. After precooling and stirring in an ice-salt bath (-10 to -20°C), add 0.5 g of NaNO 2 The mixture was stirred in the reaction buffer for 20 min, and then 50 mL of Mesna (50 mM) was directly added to adjust the pH to 5.0. The reaction mixture was stirred at room temperature for 20-30 min. After trypsin cleavage and LC-MS identification, SUMO-C 4 H 7 N fluorescent probe.

[0025] The use of the SUMOylation capture probe of the present invention for detecting SUMOylation modification includes cellular localization, quantitative analysis and / or dynamic modification change analysis of SUMOylation modification, and these characteristics are used in the preparation of reagents for cancer diagnosis and / or prognosis.

[0026] The present invention uses gene cloning to obtain a polypeptide encoding human SUMO-1 protein, and obtains SUMO-C by chemical synthesis. 4 H 7N has a stable structure, which is convenient for chemical synthesis and detection applications. 4 H 7 The N fluorescent probe has high specificity and high sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0027] Figure 1 This is the three-dimensional spatial structure diagram of the human SUMO-1 molecule.

[0028] Figure 2 Mass spectra for SUMO protein identification.

[0029] Figure 3 SUMO-1-C 4 H 7 N fluorescence probe identification mass spectrum.

[0030] Figure 4 SUMO-1-C 4 H 7 Schematic diagram of the imaging effect of N fluorescent probe molecules in MCF7. DETAILED DESCRIPTION

[0031] The present invention is further described below by way of embodiments in conjunction with the accompanying drawings.

[0032] Example 1

[0033] Cloning and expression of human SUMO-1 gene

[0034] Total RNA was extracted from human breast cancer MCF-7 cells, mRNA was purified, mRNA was reverse transcribed, and cDNA library was constructed. Primers were designed and PCR was used to screen the human SUMO1 gene. The 5' end primer was 5'-ATGTCTGACCAGGAGGCAAAACCT-3' (SEQID NO: NM_003352.8), and the 3' end primer was 5'-CTAAACTGTTGAATGACCCCCCGT-3' (SEQ ID NO: NM_003352.8). The obtained positive monoclonal was sequenced for gene nucleotide sequencing. Gene sequencing results showed that the sequence encoding human SUMO-1 consisted of 306 nucleotides, and the sequence from 5' to 3' was (SEQ ID NO: 1):

[0035] 1ATGTCTGACC AGGAGGCAAA ACCTTCAACT GAGGACTTGG GGGATAAGAA

[0036] 51GGAAGGTGAA TATATTAAAC TCAAAGTCAT TGGACAGGAT AGCAGTGAGA

[0037] 101TTCACTTCAA AGTGAAAATG ACAACACATC TCAAGAAACT CAAAGAATCA

[0038] 151TACTGTCAAA GACAGGGTGT TCCAATGAAT TCACTCAGGT TTCTCTTTGA

[0039] 201GGGTCAGAGA ATTGCTGATA ATCATACTCC AAAAGAACTG GGAATGGAGG

[0040] 251AAGAAGATGT GATTGAAGTT TATCAGGAAC AAACGGGGGG TCATTCAACA

[0041] 301GTTTAG

[0042] SUMO-1 is a structural component of SUMO-1 (SEQ ID NO:2; NP_001005781.1):

[0043] Met-Ser-Asp-Gln-Glu-Ala-Lys-Pro-Ser-Thr-Glu-Asp-Leu-Gly-Asp-Lys-Lys-Glu-Gly-Glu-Tyr-Ile-Lys-Leu-Lys-Val-Ile-Gly-Gln-Asp-Ser-Ser-Glu-Hys-Hys -Lys-Met-Thr-Thr-His-Leu-Lys-Lys-Leu-Lys-Glu-Ser-Yyr-Cys-Gln-Arg-Gln-Gly-Va l-Pro-Met-Asn-Ser-Leu-Arg-Phe-Leu-Phe-Glu-Gly-Gln-Arg-Ile-Ala-Asp-Asn-His-Th r-Pro-Lys-Glu-Leu-Gly-Met-Glu-Glu-Glu-Asp-Val-Ile-Glu-Val-Tyr-Gln-Glu-Gln-Thr-Gly-Gly-His-Ser-Thr-Val

[0044] (MSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESY CQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGGHSTV)

[0045] The three-dimensional structure of human SUMO-1 molecule is as follows Figure 1 shown.

[0046] Specifically, the cloning of the gene of SUMO-1 molecule includes:

[0047] 1) Total RNA extraction from human MCF7 cells:

[0048] ① Take MCF7 cells cultured in a 35 mm culture dish, add 1 ml RNAiso Plus (Trizol, TAKARA, Japan), place on a decolorization shaker, and lyse for 5 minutes at room temperature.

[0049] ② Transfer the cell lysate to a 1.5 mL centrifuge tube, add 200 μL of chloroform to the tube, shake vigorously for 15 seconds, and let stand at room temperature for 5 minutes.

[0050] ③Put the centrifuge tube in ② into a low-temperature refrigerated centrifuge and centrifuge at 12000 rpm for 15 minutes at 4°C.

[0051] ④ Transfer the supernatant to a 1.5 mL RNase-Free centrifuge tube, add 500 μL of isopropanol, gently invert the centrifuge tube to mix the liquid, and let it stand at room temperature for 10 minutes.

[0052] ⑤ Place the centrifuge tube in ④ into a low-temperature refrigerated centrifuge and centrifuge at 12000 rpm for 10 min at 4°C.

[0053] ⑥ Remove the supernatant, add 1 mL of 75% ethanol to the centrifuge tube, and gently pipette to precipitate the RNA.

[0054] ⑦ Place the centrifuge tube in ⑥ into a low-temperature refrigerated centrifuge and centrifuge at 5000 rpm for 3 minutes at 4°C.

[0055] ⑧ Carefully remove the supernatant with a pipette and leave it at room temperature for a few minutes to dry the RNA.

[0056] ⑨ Add 30 μL of RNase-Free water to the centrifuge tube in ⑧ to dissolve the RNA.

[0057] 2) Construction of human cDNA library:

[0058] I.cDNA first strand synthesis (mRNA reverse transcription):

[0059] ① Add 1.0 μL of total RNA from human MCF7 cells, 1.0 μL of Oligo(dT)primer and 5.0 μL of RNase-Free ddH 2O, make the total volume reach 7 μL, mix well and centrifuge briefly (2000 rpm, 30 s), incubate at 72°C for 10 minutes after centrifugation; after incubation, incubate the centrifuge tube at 4°C for 2 minutes.

[0060] ② Add the following reagents to the above centrifuge tube: 2.0μL 5×M-MLV Buffer, 0.5μL 10mM dNTPMix, 0.5μL 40U / μL RNase Inhibitor and 0.25μL RTase M-MLV. Mix the reagents in the centrifuge tube and centrifuge briefly (2000rpm, 30s). Incubate at 42℃ for 60min, then at 70℃ for 15s. After incubation, place the centrifuge tube on ice to terminate the synthesis and set aside.

[0061] II. Amplification of SUMO1 gene by polymerase chain reaction (PCR):

[0062] ① Mix 1 μL cDNA template, 0.25 μL Taq enzyme, 10 μL 5× PCR buffer, 1 μL 10 mM dNTP, 1.0 μL 5' PCR primer, 1.0 μL 3' PCR primer and 35.75 μL ddH 2 O was mixed in a PCR tube and centrifuged to allow the mixture to accumulate at the bottom of the tube.

[0063] ② Amplify in a PCR instrument according to the following program: 95℃, 5min; 35 cycles: 94℃, 30sec, 56℃, 30sec, 72℃, 1min. After the cycle, incubate at 72℃ for 10min and store in a -80℃ refrigerator after PCR.

[0064] 3) Human SUMO-1 gene cloning and screening:

[0065] After the PCR reaction, the PCR reaction product was electrophoresed using 1% agarose gel. After 30 minutes of constant voltage at 120V, it was placed in a gel imager for observation and photography. The gel containing the target fragment of SUMO-1 was cut and recovered using an agarose gel DNA recovery kit. The recovered target fragment was connected to the pGEX-4T-3 vector and transformed into DH5α competent cells. The plate was coated and double screened with ampicillin and blue-white staining. A single colony was picked and the size of the inserted fragment was detected by PCR with M13 primers. Positive colonies were picked, and plasmids were extracted by shaking, followed by nucleotide sequencing and translation into amino acid sequences.

[0066] 4) SUMO protein expression and in vitro purification

[0067] pGEX-4T-3-SUMO1 was transformed into E. coli BL21, and positive clones were screened and cultured in shake flasks until the logarithmic growth phase. After induction with IPTG for 4 hours, the culture was continued for 16 hours, and then ultrasonically broken. The protein was purified by affinity purification column and identified by MS (such as Figure 2 ).

[0068] Example 2: SUMO-C 4 H 7 N-probe molecule synthesis

[0069] 1) In a 100 mL conical flask, dissolve ethyl benzothiazole-2-carboxylate (3.5 g, 14.5 mmol) in DMSO (60 mL), add hydrazine hydrate (70%, 1.1 mL, 35.2 mmol), reflux until the reaction is complete, and cool the system to room temperature.

[0070] 2) Add deionized water to the reaction product in step 1) and stir for half an hour to quench the reaction.

[0071] 3) adding the reaction product in step 2) to a thiophenol solution and adjusting the final pH value to 8.5, wherein the thiophenol solution is prepared by dissolving thiophenol in dimethyl sulfoxide, and the volume fraction of thiophenol is 2%.

[0072] 4) The mixture was dissolved in a mixed solution of TFA:DCM=1:1 by volume, stirred at room temperature for 1 h, monitored by TLC, and the organic phase was concentrated in vacuo, and the residue was dried under high vacuum overnight.

[0073] 5) The organic solvent in step 4) was dried by rotary evaporation, and then recrystallized with DMSO to obtain a light yellow solid powder, which was then detected by mass spectrometry.

[0074] 6) Amine hydrolysis of Boc-protected SUMO1-Mesna: SUMO1-Mesna (8.8 mg, 3.33 mM) and Boc 2 O (3.6 μL, 53 mM) was dissolved in 300 μL DMSO. Then 1.6 μL DIEA was added, stirred at room temperature for 1 h, and cold ether was added to precipitate Boc-protected SUMO1-Mesna. Subsequently, the ether precipitate was dissolved in 500 μL DMSO. Then 5 mL of thiophenol solution was added, wherein the thiophenol solution was thiophenol dissolved in dimethyl sulfoxide, and the volume fraction of thiophenol was 2%. In addition, DIEA was added as an initiator and the reaction was carried out at 37 ° C. The organic phase was precipitated with ice ether and dried after 2 h. Then a standard cleavage reagent (volume ratio of TFA / TIS / H 2 O=95:2.5:2.5) to remove the Boc group in the SUMO segment, and the crude product was obtained by precipitation with cold ether and centrifugation.

[0075] 7) In a 250 mL single-mouth bottle, add 4 g of the light yellow powder (15.6 mmol) obtained in step 5) and 2 mg of the product obtained in step 6), and add 30 mL of toluene and 20 mL of K 2 CO 3 Aqueous solution (2M) and 10 mL of anhydrous ethanol mixed solvent (volume ratio: 3:2:1). The reaction container was filled with N 2 After sealing, the mixture was placed in a shaker and reacted at 50°C and 150 rpm for about 48 hours.

[0076] 8) SUMO1-NHNH obtained in step 7) 2 (1mM) dissolved in a buffer solution (containing 6.0M GnHCl, 0.2M Na 2 HPO 4 , pH 3.0). After precooling and stirring in an ice-salt bath (-10 to -20°C), add 0.5 g of NaNO 2 The mixture was stirred in the reaction buffer for 20 min, and then 50 mL of Mesna (50 mM) was added directly to adjust the pH to 5.0. The reaction mixture was stirred at room temperature for 20-30 min. After trypsinization, LC-MS identification (such as Figure 3 ).

[0077] Example 3: SUMO-C 4 H 7 Application of N-probe molecules in MCF7 cells

[0078] MCF7 cells were inoculated into 35 mm cell culture plates, and fusion experiments were performed when the cell confluence reached about 40%. 4 H 7 The N probe molecules were co-incubated with MCF7 cells and detected by fluorescence microscopy after 36 hours. Figure 4 shown.

[0079] The probe detection method is:

[0080] Since SUMO protein can specifically recognize the lysine residues of substrate proteins, the modified proteins convert SUMO-C to SUMO through the action of enzymes related to the SUMO process. 4 H 7 The N probe molecule directly binds to the substrate. Since the probe molecule can spontaneously fluoresce with an excitation wavelength of 483nm and an emission wavelength of 515nm, the intracellular SUMO modification can be located, quantified, and dynamically monitored by detecting the intensity and position of the spontaneous fluorescence emission of the probe molecule.

Claims

1. A SUMOylation-modified capture probe, characterized in that: The SUMOylation capture probe has the molecular formula SUMO-C7H 13 NO2, the structural formula is shown in the following formula (I): The SUMO is human SUMO-1, whose nucleotide sequence is shown in SEQ ID NO: 1, and whose amino acid sequence is shown in SEQ ID NO:

2.

2. The method for synthesizing a SUMOylation-modified capture probe according to claim 1, characterized in that: The following steps are involved: Step 1: Obtain the full-length cDNA sequence of human SUMO by gene cloning; Step 2, the plasmid containing the full-length SUMO cDNA sequence obtained in step 1 is used to recombinantly express the SUMO protein polypeptide in Escherichia coli, and affinity purifies the SUMO protein polypeptide to obtain a pure SUMO protein polypeptide; Step 3: The pure SUMO protein polypeptide obtained in step 2 is synthesized by a fully chemical method to obtain a SUMO-C4H7N fluorescent probe.

3. The synthesis method according to claim 2, characterized in that The step 3 is as follows: Step 3.1) 3.5 g of ethyl benzothiazole-2-carboxylate was dissolved in 60 mL of DMSO, and then 1.1 mL of 70% by mass hydrazine hydrate was added, and the mixture was refluxed until the reaction was complete, and the system was cooled to room temperature; Step 3.2) Add deionized water to the reaction product in step 3.1) and stir for half an hour to quench the reaction; Step 3.3) adding the reaction product in step 3.2) to a thiophenol solution and adjusting the final pH to 8.5; wherein the thiophenol solution is prepared by dissolving thiophenol in dimethyl sulfoxide, and the volume fraction of thiophenol is 2%; Step 3.4) The mixture obtained in step 3.3) was dissolved in a solution of TFA and DCM in a volume ratio of 1:1, stirred at room temperature for 1 h, monitored by TLC, and the organic phase was concentrated in vacuo, and the residue was dried under vacuum overnight; Step 3.5) The organic solvent in step 3.4) is dried by rotary evaporation, and then recrystallized with DMSO to obtain a light yellow solid powder, which is then detected by mass spectrometry; Step 3.6) Aminohydrolysis of Boc-protected SUMO1-Mesna: 8.8 mg SUMO1-Mesna and 3.6 μL Boc2O were dissolved in 300 μL DMSO; then 1.6 μL DIEA was added, stirred at room temperature for 1 h, and cold ether was added to precipitate Boc-protected SUMO1-Mesna; then, the ether precipitate was dissolved in 500 μL DMSO; then 5 mL thiophenol solution was added, wherein the thiophenol solution was prepared by dissolving thiophenol in dimethyl sulfoxide, and the volume fraction of thiophenol was 2%; in addition, DIEA was added as an initiator, and the reaction was carried out at 37°C; the organic phase was precipitated with ice ether and dried after 2 h; then the Boc group in the SUMO segment was removed with a standard cleavage reagent, and a crude product was obtained by precipitation with cold ether and centrifugation; the volume ratio of TFA, TIS, and H2O in the standard cleavage reagent was 95:2.5:2.5; Step 3.7) 4 g of the light yellow powder obtained in step 3.5) and 2 mg of the product obtained in step 3.6) were mixed, and 30 mL of toluene, 20 mL of a 2M K2CO3 aqueous solution and 10 mL of anhydrous ethanol were added as a mixed solvent; the reaction container was sealed with N2, placed in a shaker, and reacted at 50°C and 150 rpm for 48 h to obtain SUMO1-NHNH2; Step 3.8) Dissolve the 1 mM SUMO1-NHNH2 obtained in step 3.7) in a buffer solution containing 6.0 M GnHCl and 0.2 M Na2HPO4 at a pH of 3.0; precool and stir in an ice-salt bath at -10 to -20°C, add 0.5 g of NaNO2 to the reaction buffer solution for 20 min, and then directly add 50 mL of Mesna to adjust the pH to 5.0; stir the reaction mixture at room temperature for 20-30 minutes; after trypsin cleavage, identify by LC-MS to obtain the SUMO-C4H7N fluorescent probe.

4. The SUMOylation modification capture probe according to claim 1 is used to detect SUMOylation modification.

5. The use according to claim 4, characterized in that: The detection of SUMOylation modification includes cell localization, quantitative analysis and / or dynamic modification change analysis of SUMOylation modification.

6. The use according to claim 5, characterized in that SUMOylation-modified capture probes are used to prepare reagents for cancer diagnosis and / or prognosis.